NeurAxis, Inc.
AMEX:NRXSBiotechnology
+$0.29 today
- Market cap
- $69.12M
- Beta
- 1.41
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.67
Volume 0.23M
Average 0.18M
NRXS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
NeurAxis, Inc.AMEX: NRXS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$1.72M, compared with -$2.27M a year earlier. Trailing-twelve-month EBITDA was -$7.12M.
Context
- EBITDA amounted to 214.8% of revenue in FY2025, down 79.4 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$5.38M (+29.9%) for the fiscal year ending Dec 2026, a step up from the +3.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.72M-3.8% QoQ
- Last fiscal yearDec 2025
- -$7.67M+3.0% YoY
- LTMMar 2026
- -$7.12M+12.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +24.3% | -147.5% | -171.8 pp |
| 1 year | +3.0% | +29.9% | +26.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (7.67M) USD
- Year-over-year change
- +3.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.67M) | +3.0% |
| FY2024 | 2024-12-31 | (7.9M) | +14.4% |
| FY2023 | 2023-12-31 | (9.23M) | -113.3% |
| FY2022 | 2022-12-31 | (4.33M) | -46.4% |
| FY2021 | 2021-12-31 | (2.95M) | — |
EBITDA vs competitors
How NRXS compares with its peers on the latest reported figures
- NRXS's LTM Mar 2026 EBITDA of -$7.12M is the highest of the 4 companies compared; the peer median is -$28.06M.
- Its year-over-year change of +12.3% is the 2nd highest of 4, against a peer median of +2.5%.
- EBITDA amounts to 166.2% of revenue for NRXS, versus a peer median of 3270.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NRXSNeurAxis, Inc. | LTM Mar 2026 | -$7.12M | +12.3% | — | 166.2% |
| LTM Dec 2025 | -$14.32M | +2.5% | — | — | |
| LTM Mar 2026 | -$28.06M | +44.2% | — | 3270.4% | |
| LTM Jun 2026 | -$394.35M | -3608.6% | — | — | |
| Peer median (excluding NRXS) | -$28.06M | +2.5% | — | 3270.4% | |
Competitors are the stored peer set for NRXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.72M | 2.68M | 2.46M | 2.69M | 3.57M |
| Cost of Revenue | 467.66K | 297.06K | 303.35K | 362K | 562.92K |
| Gross Profit | 2.25M | 2.39M | 2.16M | 2.32M | 3.01M |
| Gross Margin | 82.8% | 88.9% | 87.7% | 86.5% | 84.2% |
| Research & Development | 203.41K | 225.61K | 169.32K | 206.11K | 493.61K |
| Selling, General & Admin | 5.02M | 5.53M | 8.65M | 9.27M | 10.34M |
| Operating Expenses | 5.22M | 5.76M | 8.82M | 9.48M | 10.84M |
| Depreciation & Amortization | 36.71K | 37.13K | 40.73K | 37.83K | 59.5K |
| EBITDA | (2.95M) | (4.33M) | (9.23M) | (7.9M) | (7.67M) |
| EBITDA Margin | -108.6% | -161.1% | -375.1% | -294.2% | -214.8% |
| Operating Income | (2.97M) | (3.37M) | (6.66M) | (7.16M) | (7.83M) |
| Operating Margin | -109.1% | -125.6% | -270.9% | -266.5% | -219.4% |
| Interest Income | 0 | (2.32M) | (2.77K) | 0 | 0 |
| Interest Expense | 36.93K | 417.6K | 5.36M | 300.72K | 73.97K |
| Other Income / Expenses | (58K) | (1.41M) | (7.96M) | (1.08M) | 29.35K |
| Income Before Tax | (3.03M) | (4.78M) | (14.63M) | (8.24M) | (7.8M) |
| Pre-Tax Margin | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (3.03M) | (4.78M) | (14.63M) | (8.24M) | (7.8M) |
| Net Margin | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% |
| EPS (Basic) | (0.62) | (0.57) | (2.32) | (1.22) | (0.95) |
| EPS (Diluted) | (0.62) | (0.78) | (2.32) | (1.22) | (0.95) |
| Weighted Avg Shares | 5.38M | 8.41M | 6.3M | 6.92M | 9.08M |
| Weighted Avg Shares (Diluted) | 5.38M | 8.41M | 6.3M | 6.92M | 9.08M |
NeurAxis, Inc.
AMEX:NRXS
Intrinsic Alpha fair value
Locked
Current Price
$4.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.